Background Advances in interventional techniques now allow for transcatheter treatment of
some ventricular septal defects (VSD), although there remain concerns about adverse …

Background While percutaneous device closure (PDC) is a first‐line therapy for isolated
muscular ventricular septal defects (mVSD), surgery is still the preferred approach for peri …

The American Heart Association makes every effort to avoid any actual or potential conflicts
of interest that may arise as a result of an outside relationship or a personal, professional, or …

Thrombosis has long been recognized as a potentially lifethreatening complication in
children with congenital heart disease (CHD), children with acquired heart disease, and in …

The management of congenital heart disease has changed dramatically over the last 15
years and continues to evolve at a rapid pace. More than ever before contemporary practice …

Three-dimensional echocardiography (3DE) has become important in the management of
patients with congenital heart disease (CHD), particularly with pre-surgical planning …

BACKGROUND: Ventricular septal defect (VSD) is the most commonly recognized
congenital heart defect. With the development of device closure for intracardiac defects, we …

Objectives: The objective of this study was to evaluate the safety and efficacy of the surgical
versus transcatheter approach to correct perimembranous ventricular septal defects …

Aims The aim of this study was to evaluate the safety and efficacy of transcatheter closure for
perimembranous ventricular septal defect (pmVSD) and its long-term results. The most …

The Amplatzer muscular VSD occluder was approved by the Food and Drug Administration
in 2007 and is currently the only device approved for VSD closure in the United States. The …